0000000000625748

AUTHOR

Grossi Paolo

0000-0003-2883-5061

showing 5 related works from this author

Knowledge, Attitudes, and Smoking Behaviours among Physicians Specializing in Public Health: A Multicentre Study

2014

Background. Healthcare professionals have an important role to play both as advisers—influencing smoking cessation—and as role models. However, many of them continue to smoke. The aims of this study were to examine smoking prevalence, knowledge, attitudes, and behaviours among four cohorts physicians specializing in public health, according to the Global Health Profession Students Survey (GHPSS) approach.Materials and Methods. A multicentre cross-sectional study was carried out in 24 Italian schools of public health. The survey was conducted between January and April 2012 and it was carried out a census of students in the selected schools for each years of course (from first to fourth year …

Genetics and Molecular Biology (all)MaleHealth Knowledge Attitudes PracticeMEDICAL-STUDENTSImmunology and Microbiology (all)Cross-sectional studymedicine.medical_treatmentlcsh:MedicinecurriculumSettore MED/42 - Igiene Generale E ApplicataBiochemistryGHPSS questionnairehealth behaviorPROFESSIONS STUDENT SURVEY; TOBACCO USE; MEDICAL-STUDENTS; CESSATION; DEPENDENCE; SCHOOLS; GHPSSDEPENDENCESurveys and QuestionnairesGlobal healthSurveys and Questionnairesmoking behaviourMedicine (all)SmokingAttendanceTOBACCO USEGeneral MedicineMiddle Agedcohort analysismulticentre studyTest (assessment)femalesmoking; prevention.; public healthPublic Healthhealth care personneGHPSSResearch ArticleHumanCohort studyAdultmedicine.medical_specialtyArticle SubjectAttitude of Health PersonneleducationBiochemistry Genetics and Molecular Biology (all); Immunology and Microbiology (all); Medicine (all)General Biochemistry Genetics and Molecular BiologySCHOOLScohort analysis; controlled study; cross-sectional study; curriculum; female; GHPSS questionnaire; health behavior; health care personnemedicineHumanscross-sectional studycontrolled studyCurriculumBiochemistry Genetics and Molecular Biology (all)General Immunology and Microbiologybusiness.industryPublic healthlcsh:RFamily medicineSmoking cessationSmoking CessationPROFESSIONS STUDENT SURVEYCESSATIONbusinessBioMed Research International
researchProduct

Estimating minimum adult HIV prevalence: A cross-sectional study to assess the characteristics of people living with HIV in Italy

2015

In 2012, we conducted a retrospective cross-sectional study to assess the number of people living with HIV linked to care and, among these, the number of people on antiretroviral therapy. The health authority in each of the 20 Italian Regions provided the list of Public Infectious Diseases Clinics providing antiretroviral therapy and monitoring people with HIV infection. We asked every Public Infectious Diseases Clinic to report the number of HIV-positive people diagnosed and linked to care and the number of those on antiretroviral therapy during 2012. In 2012, 94,146 people diagnosed with HIV and linked to care were reported. The majority were males (70.1%), Italians (84.4%), and aged betw…

AdultMalePediatricsmedicine.medical_specialtyImmunology; Infectious Diseases; VirologySettore MED/17 - Malattie InfettiveEpidemiologyCross-sectional studyImmunologyHuman immunodeficiency virus (HIV)MEDLINEHIV Infectionsmedicine.disease_causeAdult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Cross-Sectional Studies; Female; HIV Infections; Humans; Italy; Male; Middle Aged; Prevalence; Retrospective StudiesVirologymedicinePrevalenceHumansHIV InfectionHIV prevalence ItalyRetrospective StudiesCross-Sectional StudieAdult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Cross-Sectional Studies; Female; HIV Infections; Humans; Italy; Male; Middle Aged; Prevalence; Retrospective Studies; Immunology; Virology; Infectious Diseasesbusiness.industryTransmission (medicine)HIVRetrospective cohort studyMiddle AgedHiv prevalenceNorthern italyCD4 Lymphocyte CountCross-Sectional StudiesInfectious DiseasesAnti-Retroviral AgentsItalyAnti-Retroviral AgentFemalebusinessViral loadHumanDemography
researchProduct

Management of infections in cirrhotic patients: Report of a Consensus Conference

2014

a b s t r a c t The statements produced by the consensus conference on infection in end-stage liver disease promoted by the Italian Association for the Study of the Liver, are here reported. The topics of epidemiology, risk factors, diagnosis, prophylaxis, and treatment of infections in patient with compensated and decompensated liver cirrhosis were reviewed by a scientific board of experts who proposed 26 statements that were graded according to level of evidence and strength of recommen- dation, and approved by an independent jury. Each topic was explored focusing on the more relevant clinical questions. By systematic literature search of available evidence, comparison and discussion of e…

Fungal infectionLiver Cirrhosismedicine.medical_specialtyAntifungal Agentsmedia_common.quotation_subjectInfectionsGastroenterologyBacterial infection; Cirrhosis; Fungal infections; Infections; Anti-Bacterial Agents; Antifungal Agents; Bacterial Infections; Evidence-Based Medicine; Humans; Liver Cirrhosis; Mycoses; Hepatology; GastroenterologyLiver diseaseFungal infectionsJuryInternal medicineEpidemiologymedicineHumansIn patientGrading (education)Bacterial infection; Cirrhosis; Fungal infections; Infectionsmedia_commonCirrhosiEvidence-Based MedicineHepatologybusiness.industryConsensus conferenceGastroenterologyEvidence-based medicineBacterial Infectionsmedicine.diseaseAnti-Bacterial AgentsMycosesCirrhosisFamily medicineBacterial infectionbusinessInfectionSystematic search
researchProduct

Combination of aztreonam, ceftazidime–avibactam and amikacin in the treatment of VIM-1 Pseudomonas aeruginosa ST235 osteomyelitis

2021

Abstract We describe a challenging case of patient with metallo-beta-lactamase-producing Pseudomonas aeruginosa sternal osteomyelitis following aortic valve replacement with biological prosthesis. The strain exhibited a multidrug-resistance phenotype carrying the blaVIM-1 gene and belonged to the high-risk clone sequence type ST235. The patient was successfully treated with surgical debridement plus antibiotic therapy with ceftazidime/avibactam, aztreonam, and amikacin. Time-kill curves showed that this triple antibiotic combination at 1 × MIC was strongly synergic after 8 h, achieving 99.9% killing and maintaining this until 48 h.

Microbiology (medical)AvibactamDrug ResistanceCeftazidimeInfectious and parasitic diseasesRC109-216Aztreonammedicine.disease_causeST235CeftazidimeMicrobiologyCeftazidime–avibactamchemistry.chemical_compoundAztreonamAortic valve replacementDrug TherapyDrug Resistance Multiple BacterialmedicineHumansPseudomonas InfectionsPseudomonas aeruginosa; ST235; VIM-1; aztreonam; ceftazidime-avibactam; osteomyelitisAmikacinAgedPseudomonas aeruginosabusiness.industryceftazidime-avibactamOsteomyelitisBacterialOsteomyelitisGeneral MedicineCeftazidime/avibactammedicine.diseaseAnti-Bacterial AgentsDrug CombinationsInfectious DiseaseschemistryDebridementAmikacinPseudomonas aeruginosaCombinationVIM-1Drug Therapy CombinationFemalebusinessAzabicyclo CompoundsMultiplemedicine.drug
researchProduct

The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives

2021

INTRODUCTION: The COVID-19 pandemic has dramatically challenged the national health systems worldwide in the last months. Dalbavancin is a novel antibiotic with a long plasmatic half-life and simplified weekly administration regimens, thus representing a promising option for the outpatient treatment of Gram-positive infections and the early discharge of hospitalized patients. Dalbavancin is approved for the treatment of acute bacterial skin and skin structure infections (ABSSSIs). Many preliminary data seem to support its use in other indications, such as osteomyelitis, prosthetic joint infections, and infective endocarditis. AREAS COVERED: A search in the literature using validated keyword…

0301 basic medicineMicrobiology (medical)medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)medicine.drug_classProsthetic joint030106 microbiologyAntibioticsGram-Positive Bacterial InfectionABSSSIsMicrobiologyDrug Administration Scheduleosteomyelitis.endocarditi03 medical and health sciencesABSSSIs; COVID-19; dalbavancin; endocarditis; Gram-positive; long-acting; osteomyelitisGram-positive0302 clinical medicineVirologyPandemicAnti-Bacterial AgentmedicineAmbulatory CareAnimalsHumans030212 general & internal medicineIntensive care medicineGram-Positive Bacterial Infectionsbusiness.industryAnimalOsteomyelitisDalbavancinCOVID-19osteomyelitisSkin Diseases Bacteriallong-actingABSSSImedicine.diseaseAnti-Bacterial AgentsInfectious DiseasesInfective endocarditisSkin structureendocarditisosteomyelitiTeicoplaninbusinessdalbavancinHuman
researchProduct